Genoimmune Therapeutics Co., Ltd.

Bgi Shenzhen

Bgi Tech Solutions Co., Ltd

Bgi-shenzhen Co., Limited

Yong Hou

Shuntao Luo

Xiumei Lin

Bo Li

Ting An

Ying Huang

Yunxia Tang

Geng Liu

Guanglei Li

Handong Li

Chengchi Chao

Wei Zhang

Fei Wang

Ye Tao

Xun Xu

Yan Liang

Shida Zhu

Dongli Li

Naibo Yang

Cheng Cheng

Zhen Cheng

Shilei Wang

Kui Wu

Yuelu Yin

Kun Duan

Luting Song

Di Shao

Zequn Zheng

Zhijun Zheng

Shuheng Liang

Si Qiu

Chongming Jiang

Weiming He

Li Bao

Fuqiang Li

Xiaofei Ye

Provided is a MART-1 (27-35) epitope-specific T cell receptor, comprising an α chain and a β chain. The α chain comprises three complementary determining regions, respective sequences thereof being positions 61-66, positions 84-89, and positions 124-136 of SEQ ID No. 3. The β chain comprises three complementary determining regions, respective amino acid sequences thereof being positions 46-50, positions 68-73, and positions 112-125 of SEQ ID No. 4. A T cell expressing the TCR can effectively recognize a MART-1 (27-35) epitope polypeptide supported on a T2 cell and secrete IFN-γ, thereby demonstrating the functionality of the receptor. Use of the TCR with a relevant drug target allows for effective drug development.

MART-1(27-35) epitope-specific T cell receptor

The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.

Tumor-specific polypeptide and use thereof

Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Polypeptide and use thereof

Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

Col14A1-derived tumor antigen polypeptide and use thereof

Provided are a tumor antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding the same; a nucleic acid construct, an expression vector, and a host cell containing the encoding nucleic acid; and an antigen presenting cell presenting the tumor antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

CACNA1H-derived tumor antigen polypeptide and use thereof

Provided are the method and device for genetic map construction and the method and device for haplotype determination of a single cell. Wherein the method for genetic map construction includes: whole genome sequencing for at least a single cell from a same species, aligning the sequencing data to reference sequences respectively to determine genotypes of SNP sites, determining male parent a/female parent b typing results of SNP genotypes of a single cell based on the genotypes of SNP sites, dividing the chromosome of the species into linkage regions based on the male parent a/female parent b typing results of SNP genotypes, determining the variation ratio of a/b between two linkage regions to obtain recombination rate between every two continuous linkage regions, determining recombination map of a single cell according to the recombination rate, wherein the boundary site of a and b is the recombination site, determining the recombination rate of each recombination rate based on the recombination map to construct a genetic map of the species.

Method and device for genetic map construction, method and device for haplotype analysis

Growing community of inventors

Shenzhen, China

Yong Hou